JPRN-C000000352CompletedPhase 2
Evaluation of safety and tolerability of the initial treatment with imatinib for chronic myeloid leukemia in chronic phase (Tokyo STI Study Group) - Evaluation of safety and tolerability of imatinib for CML-CP (TSSG study)
Tokyo STI Study Group0 sites100 target enrollmentStarted: March 10, 2006Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 15years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Pregnant and/or lactating woman 2)WBC<3000/mm3 3)serum bilirubin or creatinine level above twice as the upper limit of normal 4)GPT or GOT level above 3 times as the upper limit of normal 5)PS >=3 6)In accelerate or blastic phase 7)Ph positivity <30 % by IFN-a treatment 8)Past history of BMT or PBSCT 9)Receiving investigational agents within 4 weeks 10)Grade 3 heart failure 11)Receiving another anti-leukemic therapy including IFN-a
Investigators
Similar Trials
Completed
Not Applicable
A phase I study of the safety, tolerability, and antitumor activity of escalating doses of combretastatin A4 phosphate given in combination with bevacizumab to subjects with advanced solid tumorsAdvanced solid tumoursSolid tumoursCancerISRCTN96787846OXiGENE, Inc. (USA)12
Withdrawn
Phase 1
Safety and tolerability of the Traditional Chinese Medicine Formulation GOPAC in patients with advanced malignancyAdvanced malignancy (palliative)Cancer - Other cancer typesACTRN12609000652279Sydney South West Area Health Service70
Recruiting
Phase 1
utetium-177-anti-Programmed Cell Death-Ligand 1 single domain antibodies (177Lu-anti-PD-L1 sdAb) in metastatic non-small cell lung cancerMetastatic Non-small Cell Lung CancerCancer - Lung - Non small cellACTRN12623000959673Radiopharm Theranostics Ltd23
Completed
Phase 1
A Phase I Study of SCC244 in Japanese Patients with Advanced Solid TumorsSolid tumorsJPRN-jRCT2080225124Shanghai Haihe Pharmaceutical Co., Ltd.6
Completed
Phase 1
Safety Study of BMS-986016 With or Without Nivolumab in Subjects With Advanced Solid TumorsAdvanced Solid TumorsJPRN-jRCT2080223428Bristol-Myers Squibb K.K.27